Brain Metastasis Clinical Trial
Official title:
Phase I, Dose Finding Trial of the Combination of Panobinostat and Stereotactic Radiation in the Treatment of Brain Tumors
This is an open label phase I clinical trial with two arms, representing single and
fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is
pre-determined and not escalated. Panobinostat will be administered orally 3 times a week
for 2 weeks. Panobinostat will be dose-escalated independently in each arm. There is no
intra-patient dose escalation.
Recurrent gliomas (Arm A) will be treated according to the Jefferson protocol for
re-irradiation, 10 fractions each of 3.5Gy delivered over 2 weeks. Panobinostat will be
administered orally three times a week for 2 weeks, starting on day 1 or 2 of radiation
therapy. High-grade meningiomas (Arm A) will be treated with 6 weeks/30 fractions of
fractionated radiation therapy, to a total dose of between 54 Gy and 60 Gy in fractions of
either 1.8Gy or 2Gy. Panobinostat will be administered orally three times a week for 2
weeks, starting on the day of 1st fraction of radiation.
Large brain metastases (Arm B) will be treated with a single fraction of radiosurgery.
Panobinostat will be administered orally three times a week for 2 weeks, starting on the day
of radiation. The radiosurgery may be delivered by either LINAC, gamma-knife, cyber-knife or
tomotherapy technology.
Brain tumors, both primary and metastatic present a therapeutic challenge. Radiation therapy
plays a major role in management of both entities. Nonetheless, local control remains
sub-optimal in a large proportion of patients. Over the previous decade there has been a
great deal of progress regarding 1) precision in the localization and targeting of brain
lesions with radiation, 2) increased use of single/hypofractionation schedules and 3)
combining fractionated conformal radiation with targeted agents. This trial utilizes a novel
approach - the combination of an HDAC inhibitor (Panobinostat) with stereotactic
radiosurgery. The combination blends the advantages of extreme high precision radiation with
a potent targeted agent - promising enhanced efficacy with minimal toxicity. The
investigators will examine the combination in three settings, in all of which current
standard of care is sub-optimal:
1. Recurrent glioma
2. High grade meningioma
3. Large brain metastases from solid malignancies
Histone deacetylase (HDAC) inhibitors, including Panobinostat, radiosensitize tumor cells
both in vitro and in vivo. HDAC inhibitors modify the expression of approximately 8% of the
transcriptome83. In particular, they have been shown to down regulate expression of the DNA
repair enzyme rad51, possibly explaining their radiosensitization properties. It is thought
that Panobinostat radiosensitizes through an epigenetic mechanism. Since the target of HDAC
inhibitors includes many proteins beyond histones, many prefer the name "deacetylase
inhibitors", (DAC).
There are several lines of evidence suggesting HDAC inhibitors cross the BBB. The
anticonvulsant valproic acid, a member of the short chain fatty acid class of HDAC
inhibitors, has a well-recognized capacity to cross the BBB. HDAC inhibitors are also being
studied in Huntington's disease. Panobinostat is able to cross the blood-brain-barrier and
influence gene expression in rodents.
When combining radiation therapy with systemic agents it is generally considered important
that there is a high concentration of drug present at, or just before, the time of
irradiation. The goal is to use panobinostat as a radiosensitizer, not a single systemic
agent. The investigators will administer oral panobinostat 3 times weekly for 2 weeks. This
is an open label phase I clinical trial with two arms, representing single and fractionated
radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not
escalated. Panobinostat will be administered orally 3 times a week for 2 weeks. Panobinostat
will be dose-escalated independently in each arm. There is no intra-patient dose escalation.
Recurrent gliomas (Arm A) will be treated according to the Jefferson protocol for
re-irradiation, 10 fractions each of 3.5Gy delivered over 2 weeks. Panobinostat will be
administered orally three times a week for 2 weeks, starting on the day of 1st fraction of
radiation. High-grade meningiomas (Arm A) will be treated with 6 weeks/30 fractions of
fractionated radiation therapy, to a total dose of between 54 Gy and 60 Gy in fractions of
either 1.8Gy or 2Gy. Panobinostat will be administered orally three times a week for 2
weeks, starting on the day of 1st fraction of radiation.
Large brain metastases (Arm B) will be treated with a single fraction of radiosurgery.
Panobinostat will be administered orally three times a week for 2 weeks, starting on the day
of radiation. The radiosurgery may be delivered by either LINAC, gamma-knife, cyber-knife or
tomotherapy technology.
Radiation treatment: definition of target volumes:
Recurrent gliomas (Arm A) If progression is diagnosed with the development of new enhancing
tumor: The gross tumor volume (GTV) will be defined by the new contrast-enhanced T1
abnormality on the post-operative MRI scan. This will generally include the surgical cavity
margins from the most recent surgical procedure. If progression is diagnosed with the
development of new non-enhancing tumor: volumes will be defined through careful comparison
of new and previous MRI scans in consultation with a neuro-radiologist. This will generally
include the surgical cavity margins from the most recent surgical procedure.
The GTV will then be expanded by an additional margin of 5.0 mm to create the PTV. This 5mm
margin may be reduced, or eliminated around natural barriers to tumor growth such as the
skull, ventricles, falx, etc, and also to allow sparing of the optic nerve/chiasm or other
critical structure at the discretion of the treating physician. The minimum dose to the PTV
will be 95% of the prescription dose (35Gy). The maximum dose to the PTV will be 110%. Any
beam arrangement and set of energies that accomplishes these criteria is allowed.
High-grade meningiomas (Arm A) Target volumes will be based upon postoperative-enhanced MRI
(unless only biopsy was performed). Preoperative imaging may be used for correlation and
improved identification. The gross tumor volume (GTV) will be defined by the tumor bed on
the postoperative- enhanced MRI and is to include any residual nodular enhancement. Cerebral
edema is not to be specifically included within the GTV. The "dural tail" may or may-not be
included depending on physician preference. The clinical target volume (CTV) will be the GTV
plus a margin of between 1.0 cm and 2.0cm according to physician preference. The CTV margin
may be reduced to 0.5 cm around natural barriers to tumor growth such as the skull. The
planning target volume (PTV) is an additional margin of 3.0 to 5.0 mm, depending upon
localization method and reproducibility. PTV margins account for variations in set-up and
reproducibility. The CTV/PTV margins way be modified to allow sparing of the optic
nerve/chiasm or other critical structure at the discretion of the treating physician.
The minimum dose to the PTV will be 95% of the prescription dose (35Gy). The maximum dose to
the PTV will be 110%. Any beam arrangement and set of energies that accomplishes these
criteria is allowed.
Large brain metastases (Arm B) Single fraction radiosurgery doses will be in accordance with
prescriptions from RTOG radiosurgery trial 90-058. Metastases larger than 2 cm but equal to
or smaller than 3 cm will be treated with 18•0 Gy; and metastases larger than 3 cm and less
than or equal to 4 cm will be treated to a prescription dose of 15.0 Gy. Radiation therapy
should be planed in accordance with standard radio-surgical principals, i.e. prescribed to
the 50% isodose line for gamma-knife and 90% isosurface for LINAC based systems.
6.3 Technical aspects of radiation therapy Fractionated treatment will be highly conformal
external beam radiation therapy (EBRT) delivered with either gamma-knife, tomotherapy,
cyberknife or megavoltage LINAC radiation therapy machines of energy ≥ 6 MV. Any standard
technique of dose planning including conformal dynamic arcs, 3D-CRT or IMRT may be used.
For single fraction treatments cyber-knife, LINAC, tomotherapy or gamma-knife based
radiosurgery may be used.
Normal tissue constraints Arm A, Recurrent glioma The brain stem: no more than 1cm3 should
receive more than 30Gy; optic chiasm and optic nerves should not receive more than 25Gy,
unless included in the target volume.
Arm A, High-grade meningioma Lenses 7Gy, Retinae 50Gy, Optic Nerves 55Gy, Optic Chiasm 56Gy,
Brainstem 60Gy Arm B, Single fraction Brain stem no more than 1cm3 should receive more than
10Gy; optic chiasm and optic nerves no more than 8 Gy;
In the event that an organ at risk (OAR) is in immediate proximity to a PTV such that dose
to the OAR cannot be constrained within protocol limits, the final decision is left to the
treating physician to weigh up potential treatment toxicity versus under-coverage of target
volume.
Panobinostat for oral administration will be provided by Novartis. Medication labels will
comply with US legal requirements and be printed in English. They will supply no information
about the patient. The storage conditions for study drug will be described on the medication
label, and the investigator's brochure, edition #5 19-Jun-2009.
Panobinostat should be administrated after at least 2-hour fast, and subjects will continue
the fast for 2 more hours. If the patient misses one or more doses of panobinostat and it is
before the next dose of panobinostat is due, the patient should take the make up dose at the
earliest time, then resume the protocol schedule. If patient misses one or more doses of
panobinostat, and the patient is due for the next dose of panobinostat, the patient should
resume the protocol schedule without making up for the missing dose/doses. If the patient
misses one or more panobinostat doses and it is past the scheduled last dosing time of the
panobinostat, the patient should stop panobinostat without making up for the missing
dose/doses.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01913067 -
Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
|
Phase 2 | |
Completed |
NCT02662725 -
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
|
Phase 2 | |
Completed |
NCT00406835 -
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
|
Phase 3 | |
Completed |
NCT01724801 -
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
|
Phase 3 | |
Completed |
NCT00219297 -
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02328300 -
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
|
||
Terminated |
NCT01894633 -
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
|
Phase 2 | |
Recruiting |
NCT02681549 -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02279992 -
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
|
Early Phase 1 | |
Completed |
NCT02913534 -
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy
|
N/A | |
Completed |
NCT01942980 -
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
|
Phase 3 | |
Terminated |
NCT01363557 -
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
|
N/A | |
Active, not recruiting |
NCT05102747 -
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
|
N/A | |
Recruiting |
NCT01891708 -
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
|
N/A | |
Completed |
NCT01508221 -
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
|
Phase 2 | |
Completed |
NCT00587964 -
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
|
Phase 2 | |
Not yet recruiting |
NCT06462079 -
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
|
Phase 2 | |
Not yet recruiting |
NCT02832635 -
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
|
Phase 2 | |
Completed |
NCT01395407 -
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
|
Phase 1 | |
Terminated |
NCT02433171 -
Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
|